Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$179.38
▼ $3.72 (-2.0%)
Market data updated: 09/19 12:32 PM
Fundamentals updated: 09/19/2026
News analyzed: 09/19/2026
Market Cap
$24.07B
Day Range
$175.64 - $183.37
52-Week Range
$55.38 - $183.51
Beta
—
Next Earnings
27.10.2026
Support
$140.86
Resistance
$183.51
GH is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+205.1% (1Y)
Strengths: 19/33 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 32.9%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: -$56.41 vs. price $179.38 (-131.4%)
Fair Value
Signal tension
Growth scores strong (67/100), but fair-value analysis scores this stock as relatively expensive (38/100) — the growth story and the current price aren't fully aligned.
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
65
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
1d ago · $183.10
Evidence: Euphoria score crossed 55 (now 68)
What happened after
Still awaiting outcome
1d ago · $183.10
Evidence: FOMO score jumped from 10 to 59 day-over-day
What happened after
Still awaiting outcome
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
67
Quality
63
Value
38
Momentum
85
Risk
54
Sentiment
100
Fundamental
46
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Guardant Health has centered on two key themes: **legal and financial challenges**—notably a $245 million patent judgment—and **expanding market opportunities**. The company secured FDA approval for its **Guardant360 CDx** as a companion diagnostic for AstraZeneca’s breast cancer drug, while also expanding coverage for its **Shield blood test** through Carelon, a major U.S. medical benefits manager, for colorectal cancer screening. Analysts remain bullish, with Buy ratings and price targets, despite concerns over the patent ruling.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Guardant Health, Inc.. News trend score: 100. Reason: 13 of the last 20 articles are positive, versus 0 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
51
🎯 Conviction (vs. Emotion)
43
Psychology
67
Fundamentals
46
Technical
85
Valuation
38
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+36%
Market Narrative
75
Fundamental Reality
43
Narrative Gap
+32
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior suggests a **narrative-reality gap** (7-point divergence) where investors may perceive GH as undervalued (+26.9% above 200-day avg) despite weak momentum (-1.2% ROC) and neutral sentiment (68/100). The absence of dominant bias hints at **detached valuation**—traders may be ignoring short-term underperformance to anchor on long-term fundamentals. Key uncertainty: whether the gap persists or if momentum reverses, forcing a reassessment of overvaluation. Low volume (0.95x avg) and neutral volatility (1.00x ATR) further imply cautious, non-emotional trading.
Updated: 09/08/2026, 03:48 AM
👥 What the crowd believes
"Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer"
"Guardant Health’s Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening"
"Guardant Health ordered to pay $245M in patent dispute"
"BTIG reiterates Guardant Health with a Buy and maintains $195 price target"
🧠 Market Brain events driving this
📈 12D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Benjamin Graham — 100/100
🔴 Weakest match
Samuel Armstrong Nelson — 7/100
🗣️ Why do they disagree?
This stock splits the historical methodologies into two starkly different camps: the value-oriented fundamentalists who see strong potential and the more cautious, cyclical, or market-savvy investors who flag significant risks. Benjamin Graham’s defensive and enterprising frameworks both score maximally, signaling a rare deep-value opportunity, while Edgar Lawrence Smith and Samuel Armstrong Nelson also rate it highly as a long-term hold or cyclically oversold play. In contrast, methodologies like those of Jesse Livermore, Jack Schwager, and Howard Marks (Market Cycle) dismiss it outright, warning of late-cycle risks, lack of clear trends, or overpriced growth expectations. Even Peter Lynch and Philip Fisher, who favor growth and quality, remain lukewarm, suggesting the stock’s price already reflects its upside—leaving only moderate, not exceptional, appeal. The divide underscores whether the stock’s fundamentals justify its valuation (Graham’s camp) or if it’s already priced for perfection (Marks, Livermore, and Schwager’s skepticism).
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 100
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟢 100
Not enough valuation data for a real Enterprising-Graham read
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 20%
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 80
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟢 73
Looks like a real 'buy and hold for a decade' candidate
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟡 64
Mixed — growth exists but the price already reflects much of it
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 64
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 63
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 62
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 57
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 38
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 36
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 35
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🔴 34
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🔴 29
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🔴 23
Pattern consistent with a crowd delusion Mackay would flag
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 7
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (9 bullish · 1 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
64.5%
Operating Margin
-44.5%
Net Margin
-42.4%
EBITDA Margin
-40.5%
ROE
419.2%
ROA
-20.7%
ROIC
—
EPS
-$3.32
Cash
$378.20M
Total Debt
$1.50B
Current Ratio
4.84
Debt/Equity
-15.14
How is Fair Value calculated? →
Current Price
$179.38
Estimated Fair Value (DCF)
-$56.41
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-131.4%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
25.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 25.0% | $-291.33M | $-267.28M |
| 2 | 19.4% | $-347.78M | $-292.72M |
| 3 | 13.8% | $-395.60M | $-305.47M |
| 4 | 8.1% | $-427.74M | $-303.02M |
| 5 | 2.5% | $-438.43M | $-284.95M |
Base FCF (last actual year)
$-233.07M
Terminal Value
$-6.91B
Present Value of Terminal Value
$-4.49B
Enterprise Value
$-5.95B
Net Debt
$1.13B
Equity Value
$-7.07B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
-$0.79
Tangible Book Value per Share (Tangible NAV)
-$1.62
Sentiment based on basic keywords (not AI) — 13 positive, 7 neutral, 0 negative out of the last 20 articles.
Yahoo · 18.9.2026
Yahoo · 16.9.2026
Yahoo · 16.9.2026
Yahoo · 16.9.2026
Yahoo · 16.9.2026
Yahoo · 16.9.2026
Yahoo · 15.9.2026
SeekingAlpha · 15.9.2026
Yahoo · 14.9.2026
Business Wire · 14.9.2026
Benzinga · 14.9.2026
Yahoo · 9.9.2026
Business Wire · 9.9.2026
Benzinga · 9.9.2026
MT Newswires · 9.9.2026
Yahoo · 8.9.2026
Business Wire · 8.9.2026
Yahoo · 8.9.2026
InvestorPlace · 8.9.2026
Yahoo · 8.9.2026
Guardant Health, Inc. (GH) currently has a StockIQ AI score of 65/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
GH currently scores 65/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, GH's estimated fair value is -$56.41, which is 131.4% below the current price of $179.38. This is one valuation model among several signals in the fair-value category, not a price target.
GH's technical score is 85/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 32.9%; Operating margin is stable or improving over time; Return on equity (ROE): 419.2% — strong.
Based on the real signals StockIQ computed: Estimated fair value: -$56.41 vs. price $179.38 (-131.4%); Operating margin: -44.5% (negative); Net margin: -42.4% (negative).
StockIQ has no recorded dividend payment history for GH.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 8 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Azar Alex M II | Exercise of Derivative Securities | 12.9.2026 | 1,651 | +1,651 | — |
| Azar Alex M II | Exercise of Derivative Securities | 12.9.2026 | 1,651 | -1,651 | — |
| Kalia Kumud | Open Market Sale | 11.9.2026 | 4,000 | -4,000 | $158.05 |
| Eltoukhy Helmy | Gift | 26.8.2026 | 1,940,934 | -30,000 | — |
| Eltoukhy Helmy | Other Transaction | 26.8.2026 | 60,000 | +25,000 | — |
| Eltoukhy Helmy | Other Transaction | 26.8.2026 | 1,970,934 | -25,000 | — |
| Eltoukhy Helmy | Gift | 26.8.2026 | 30,000 | -30,000 | — |
| Eltoukhy Helmy | Other Transaction | 26.8.2026 | 25,000 | +25,000 | — |
| Eltoukhy Helmy | Other Transaction | 26.8.2026 | 25,000 | -25,000 | — |
| MIGNONE ROBERTO | Exercise of Derivative Securities | 21.8.2026 | 6,864 | -264 | — |
| Talasaz AmirAli | Open Market Sale | 21.8.2026 | 37,500 | -7,589 | $170.29 |
| MIGNONE ROBERTO | Exercise of Derivative Securities | 21.8.2026 | 10,010 | +264 | — |
| Talasaz AmirAli | Open Market Sale | 21.8.2026 | 45,089 | -20,888 | $169.16 |
| Talasaz AmirAli | Open Market Sale | 21.8.2026 | 65,977 | -9,023 | $168.20 |
| MIGNONE ROBERTO | Exercise of Derivative Securities | 21.8.2026 | 264 | +264 | — |
| Talasaz AmirAli | Open Market Sale | 21.8.2026 | 20,888 | -20,888 | $169.16 |
| Talasaz AmirAli | Open Market Sale | 21.8.2026 | 9,023 | -9,023 | $168.20 |
| MIGNONE ROBERTO | Exercise of Derivative Securities | 21.8.2026 | 264 | -264 | — |
| Talasaz AmirAli | Open Market Sale | 21.8.2026 | 7,589 | -7,589 | $170.29 |
| Hidalgo Medina Manuel | Exercise of Derivative Securities | 17.8.2026 | 232 | +232 | — |
| Hidalgo Medina Manuel | Exercise of Derivative Securities | 17.8.2026 | 232 | -232 | — |
| Tariq Musa | Open Market Sale | 17.8.2026 | 116 | -116 | $156.45 |
| Tariq Musa | Exercise of Derivative Securities | 15.8.2026 | 250 | +250 | — |
| Tariq Musa | Exercise of Derivative Securities | 15.8.2026 | 250 | -250 | — |
| Monroe Terilyn J. | Exercise of Derivative Securities | 12.8.2026 | 14,012 | -14,012 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
11,050,208 shares short as of 2026-08-31 · vs. 11,416,103 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
49.5% of trading volume this week was short selling, vs. 48.8% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology